Omelia

Olmesartan medoxomil, Hydrochlorothiazide and Amlodipine besilate, the active ingredients in Omelia, are an angiotensin II receptor blocker, thiazide diuretic and calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adults.

GNH USA supplies Omelia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omelia is a fixed‑dose combination that targets the renin‑angiotensin system, sodium balance and vascular smooth‑muscle tone to control high blood pressure.

- Hypertension: provides sustained reduction of systolic and diastolic blood pressure in patients with essential hypertension.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: warm sensation with reddening of skin. - Fatigue: general tiredness. - Increased urination: due to diuretic effect.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte imbalance: notably low potassium or sodium levels. - Acute kidney injury: rise in serum creatinine. - Angioedema: swelling of face, lips or throat. - Pancreatitis: abdominal pain with elevated enzymes. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline blood pressure, renal function and electrolyte status. - Monitor blood pressure: adjust therapy if target values are not reached. - Check renal function: periodic serum creatinine and eGFR measurements. - Assess electrolytes: especially potassium and sodium levels. - Avoid use in severe hepatic impairment: dose adjustment may be required. - Counsel patients on orthostatic dizziness: advise slow position changes. - Store at ambient temperature: keep in the original pack, protect from moisture.

Omelia may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can cause severe hypotension and renal failure. - Potassium‑sparing diuretics: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and worsen renal function. - Cyclosporine: increased nephrotoxicity. - Lithium: elevated lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors: additive blood‑pressure lowering; monitor for hypotension. - Other antihypertensives: may require dose adjustment. - CYP3A4 inhibitors (e.g., erythromycin): increase amlodipine levels. - CYP3A4 inducers (e.g., rifampin): reduce amlodipine exposure. - Antidiabetic agents: enhanced hypoglycaemic effect; monitor glucose.